LUX-Lung 7 Update: Trend for OS Benefit for Afatinib

Copenhagen, Denmark—Updated results from the Phase IIb LUX-Lung 7 trial of afatinib versus gefitinib were ...

FEBRUARY 3, 2017

Afatinib Improved Outcomes Over Gefitinib for EGFR-mutated NSCLC

First-line afatinib significantly improved outcomes in EGFR-mutated NSCLC vs gefitinib.

APRIL 27, 2016